1. Home
  2. AXGN vs AUPH Comparison

AXGN vs AUPH Comparison

Compare AXGN & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Axogen Inc.

AXGN

Axogen Inc.

HOLD

Current Price

$30.50

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.14

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AXGN
AUPH
Founded
N/A
1993
Country
United States
Canada
Employees
452
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.6B
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
AXGN
AUPH
Price
$30.50
$15.14
Analyst Decision
Strong Buy
Buy
Analyst Count
9
4
Target Price
$33.67
$17.25
AVG Volume (30 Days)
922.8K
1.1M
Earning Date
10-29-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.55
Revenue
$214,709,000.00
$265,808,000.00
Revenue This Year
$21.60
$21.76
Revenue Next Year
$15.83
$16.45
P/E Ratio
N/A
$28.99
Revenue Growth
18.72
20.62
52 Week Low
$9.22
$6.55
52 Week High
$34.24
$16.54

Technical Indicators

Market Signals
Indicator
AXGN
AUPH
Relative Strength Index (RSI) 51.59 42.04
Support Level $32.03 $15.64
Resistance Level $33.84 $15.98
Average True Range (ATR) 1.39 0.39
MACD -0.32 -0.13
Stochastic Oscillator 32.41 8.50

Price Performance

Historical Comparison
AXGN
AUPH

About AXGN Axogen Inc.

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: